Compare Cassava Sciences Inc (FLNA) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tapestry, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Tapestry, Inc. trades at $116.24 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 586× Cassava Sciences Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Tapestry, Inc. for 70 Days on average.
| FLNA | TPR | |
|---|---|---|
Market Cap | $39.40M | $23.09B |
Volume | 759,018 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $164.78 |
52-Week Low | $0.68 | $98.81 |
Typical Hold Time | 37 Days | 70 Days |
Enterprise Value | -$43.28M | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Tapestry (TPR) trades at $115.82, up 2.14% today, with strong analyst support showing 73% buy ratings and a $174.64 consensus price target. The stock demonstrates robust profitability with 77.82% gross margins and 19.09% net income margin, though recent earnings show volatility with Q3 2026 results pending. Technical indicators signal bearish momentum with price near key support at $114, while fundamentals reveal mixed trends with revenue growth projected to $8B in 2026 but net income showing significant fluctuation from $183M in 2025 to projected $1.5B in 2026.
The investment case balances strong brand positioning and international growth potential against execution risks in the Kate Spade segment and tariff pressures. With the current price representing a 34% discount to analyst targets and institutional accumulation continuing, the stock offers upside potential for patient investors willing to navigate near-term volatility and margin expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
